The synthetic lethality-based drugs and targets market is projected to grow at an annualized rate of ~18%, till 2030

Roots Analysis has done a detailed study on “Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways” covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 485+ page report, which features 195+ figures and 200+ tables, please visit this link

Key Market Insights

An analysis of recent activity on Twitter confirms the rising interest in this domain as stakeholders attempt to harness the therapeutic potential of synthetic lethality

About 75 drug candidates based on synlet gene pairs are being evaluated for the treatment of various types of cancers; presently, there are over 20 screening platforms enabling therapy development efforts

The pipeline features both small molecules and biologic drugs based on different synlet targets for treating a variety of oncological and non-oncological indications

Innovation in this domain is evident across the plethora of scientific articles published in prestigious journals, highlighting key focus areas and prevalent / upcoming trends

Over time, several non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on the identification of novel synlet targets across different clinical conditions

Significant advances in research have led to the discovery of a wide array of synlet targets; over time, substantial intellectual capital has been generated and validated by eminent scientists from renowned research institutes

To support innovation, several private and public investors have made substantial capital investments, totalling to approximately USD 5.1 billion, across 100 instances of funding

The personalized approach offered by companion diagnostics presents enormous opportunities for drug developers to partner with diagnostic test providers to improve patient / subject selection in clinical trials

Future growth of the market is likely to be driven by the success of clinical outcomes of late-stage molecules; industry stakeholders are optimistic about the vast potential of PARP inhibitors

In the mid to long term, the anticipated market opportunity is likely to be well distributed across advanced cancer indications, delivery routes and various global regions

For more information, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html

Table of Contents

PREFACE

1.1.                   Scope of the Report

1.2.                   Research Methodology

1.3.                   Chapter Outlines

EXECUTIVE SUMMARY

INTRODUCTION TO DNA DAMAGE AND REPAIR SYSTEMS

3.1.                   Chapter Overview

3.2.                   Overview of Deoxyribonucleic Acid (DNA) Damage

3.3.                   DNA Damaging Agents

3.3.1.                Endogenous DNA Damaging Agents

3.3.2.                Exogenous DNA Damaging Agents

3.3.3.                Other DNA Damaging Agents

3.4.                   DNA Damage Response System

3.4.1.                Key Components of DNA Repair System

3.5.                   Types of DNA Repair Systems

3.5.1.                Direct Repair

3.5.1.1.             Photoreactivation

3.5.1.2.             Alkyl Transferase Mediated Direct DNA Repair

3.5.1.3.             AlkB Mediated Direct DNA Repair

3.5.1.4.             DNA Ligase Mediated Direct DNA Repair

3.5.2.                Excision Repair

3.5.2.1.             Base Excision Repair (BER)

3.5.2.1.1.          BER Pathway: Key Enzymes

3.5.2.1.1.1.        DNA Glycosylases

3.5.2.1.1.2.        Apurinic / Apyrimidinic (AP) Endonucleases

3.5.2.1.1.3.        Other Enzymes

3.5.2.1.2.          Short-Patch Base Excision Repair

3.5.2.1.3.          Long-Patch Base Excision Repair

3.5.2.2.             Nucleotide Excision Repair (NER)

3.5.2.3.             Mismatch Repair

3.5.3.                Indirect Repair

3.5.3.1.             Homologous Recombination Repair (HRR)

3.5.3.2.             Non-Homologous End-Joining

3.6.                   Mutations in DNA Repair Genes

INTRODUCTION TO SYNTHETIC LETHALITY

4.1.                   Chapter Overview

4.2.                   Concept of Synthetic Lethality

4.2.1.                Historical Evolution of Synthetic Lethality

4.2.2.                HRR and Synthetic Lethality

4.2.3.                Other Synthetic Lethal Gene Interactions

4.2.4.                Advantages of Synthetic Lethality

4.2.5.                Limitations of Synthetic Lethality

4.3.                   Identification of Synlet Interactions

4.3.1.                Hypothesis-Driven Approach

4.3.2.                Screening-Based Approaches

4.3.2.1.             Chemical Library-Based Screening Approaches

4.3.2.1.1.          Non-Annotated Libraries

4.3.2.1.2.          Annotated Libraries

4.3.2.2.             Genome-Wide Interference-Based Screening Approaches

4.3.2.2.1.          Ribonucleic Acid Interference (RNAi) Based Synlet Target Identification

4.3.2.2.2.          Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Based                              Synlet Target Identification

4.3.3.                In Silico Approaches

4.4.                   Prevalent Trends Related to Synthetic Lethality

4.4.1.                Recent News on Google: Emerging Focus Areas

4.4.2.                Google Trends Analysis: Historical Timeline

4.4.3.                Google Trends Analysis: Geographical Activity

4.4.4.                Google Trends Analysis: Other Key Terms Related to Synthetic Lethality

4.5                    Concluding Remarks

MARKET OVERVIEW

5.1.                   Chapter Overview

5.2.                   Synthetic Lethality-based Drugs: Marketed and Development Pipeline

5.2.1.                Analysis by Phase of Development

5.2.2.                Analysis by Type of Molecule

5.2.3.                Analysis by Type of Therapy

5.2.4.                Analysis by Type of Synlet Target

5.2.5.                Analysis by Therapeutic Area

5.2.6.                Analysis by Target Indication

5.2.7.                Analysis by Patient Segment

5.2.8.                Analysis by Route of Administration

5.3.                   Synthetic Lethality-based Drugs: List of Screening Platforms

5.4                    Synthetic Lethality-based Drugs: List of Drug Developers / Screening Platform Providers

5.4.1.                Analysis by Year of Establishment

5.4.2.                Analysis by Location of Headquarters

5.4.3.                Analysis by Company Size

5.4.4.                Analysis by Company Size and Location of Headquarters

5.4.5.                Leading Drug Developers

COMPANY PROFILES

6.1.                   Chapter Overview

6.2.                   Profiles of Established Players

6.2.1.                AbbVie

6.2.1.1.             Company Overview

6.2.1.2.             Synthetic Lethality-based Drug Portfolio

6.2.1.2.1.          Veliparib (ABT-888)

6.2.1.3.             Recent Developments and Future Outlook

6.2.2.                AstraZeneca

6.2.2.1.             Company Overview

6.2.2.2.             Synthetic Lethality-based Drug Portfolio

6.2.2.2.1.          Olaparib (Lynparza®)

6.2.2.2.2.          AZD6738

6.2.2.2.3.          AZD1775

6.2.2.3.             Recent Developments and Future Outlook

6.2.3.                BeiGene

6.2.3.1.             Company Overview

6.2.3.2.             Synthetic Lethality-based Drug Portfolio

6.2.3.2.1.          Pamiparib (BGB-290)

6.2.3.3.             Recent Developments and Future Outlook

6.2.4.                Clovis Oncology

6.2.4.1.             Company Overview

6.2.4.2.             Synthetic Lethality-based Drug Portfolio

6.2.4.2.1.          Rucaparib (Rubraca®)

6.2.4.3.             Recent Developments and Future Outlook

6.2.5.                GlaxoSmithKline

6.2.5.1.             Company Overview

6.2.5.2.             Synthetic Lethality-based Drug Portfolio

6.2.5.2.1.          Niraparib (Zejula®)

6.2.5.3.             Recent Developments and Future Outlook

6.2.6.                Pfizer

6.2.6.1.             Company Overview

6.2.6.2.             Synthetic Lethality-based Drug Portfolio

6.2.6.2.1.          Talazoparib (TALZENNA®)

6.2.6.3.             Recent Developments and Future Outlook

6.3.                   Profiles of Small and Mid-Sized Players

6.3.1.                AtlasMedx

6.3.2.                Chordia Therapeutics

6.3.3.                IDEAYA Biosciences

6.3.4.                Mission Therapeutics

6.3.5.                Repare Therapeutics

6.3.6.                Sierra Oncology

6.3.7.                SyntheX Labs

EMERGING TRENDS ON SOCIAL MEDIA

7.1.                   Chapter Overview

7.2.                   Scope and Methodology

7.3.                   Synthetic Lethality: Trends on Twitter

7.3.1.                Cumulative Year-Wise Activity

7.3.2.                Historical Trends in Volume of Tweets

7.3.3.                Evolutionary Trend Analysis

7.3.4.                Trending Words / Phrases on Twitter

7.3.5.                Most Prolific Contributors on Twitter

7.3.6.                Most Popular Synlet Targets / Patient Mutations on Twitter

7.3.7.                Most Popular Indications on Twitter

7.3.8.                Heat Map Analysis: Distribution by Synlet Targets / Patient Mutations and                                    Indications

7.4.                   Most Popular Tweets

7.5.                   Concluding Remarks

PUBLICATION ANALYSIS

8.1.                   Chapter Overview

8.2.                   Scope and Methodology

8.3.                   Synthetic Lethality: List of Recent Publications, 2019

8.3.1.                Analysis by Type of Publication

8.3.2.                Analysis by Study Objective

8.4.                   Synthetic Lethality: Publication Analysis, 2017–2019

8.4.1.                Analysis by Year of Publication

8.4.2.                Emerging Focus Areas

8.4.3.                Analysis by Synlet Targets / Patient Mutations

8.4.3.1.             Most Popular Synlet Targets / Patient Mutations

8.4.3.2.             Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations

8.4.4.                Analysis by Target Indications

8.4.4.1.             Most Popular Target Indications

8.4.4.2.             Year-Wise Trend in Activity for Popular Target Indications

8.4.5.                Analysis by Key Research Journals

8.4.5.1.             Key Journals Based on Number of Publications

8.4.5.2.             Analysis by Journal Impact Factor

8.4.5.3.             Key Journals Based on Journal Impact Factor

8.4.6.                Key Research Hubs

8.4.7.                Most Popular Authors

8.4.8.                Analysis of Publications with Grant Support

8.4.8.1.             Most Popular Grant Bodies

8.4.8.2.             Location of Grant Bodies

8.5.                   Publication Benchmark Analysis

ABSTRACT ANALYSIS

9.1.                   Chapter Overview

9.2.                   Scope and Methodology

9.3.                   Synthetic Lethality: List of American Society of Clinical Oncology Abstracts

9.3.1.                Analysis by Year of Publication

9.3.2.                Emerging Focus Areas

9.3.3.                Most Popular Drugs

9.3.4.                Most Popular Synlet Targets / Patient Mutations

9.3.5.                Most Popular Target Indications

9.3.6.                Most Popular Principal Authors

9.3.6.1.             Analysis by Locations of Principal Authors

9.3.6.2.             Analysis by Type of Organization of Principal Authors

9.3.6.3.             Analysis by Active Organization

9.3.6.4.             Analysis by Author Designation

9.3.6.5.             Most Popular Authors



ACADEMIC GRANTS ANALYSIS

10.1.                 Chapter Overview

10.2.                 Scope and Methodology

10.3.                 Synthetic Lethality: List of Grants Awarded by National Institutes of Health

10.3.1.              Analysis by Year of Award

10.3.2.              Analysis by Amount Awarded

10.3.3.              Analysis by Administering Institute Center

10.3.4.              Analysis by Funding Institute Center

10.3.5.              Analysis by Support Period

10.3.6.              Analysis by Funding Institute Center and Support Period

10.3.7.              Most Popular National Institute of Health (NIH) Funding Categorization

10.3.8.              Analysis by Funding Mechanism

10.3.9.              Analysis by Emerging Focus Areas

10.3.10.            Most Popular Synlet Targets / Patient Mutations

10.3.11.            Most Popular Target Indications

10.3.12.            Analysis by Type of Grant Application

10.3.13.            Most Popular NIH Departments

10.3.14.            Analysis by Study Section

10.3.15.            Analysis by Type of Recipient Organization

10.3.16.            Most Popular Recipient Organization

10.3.17.            Most Popular Recipient Organization and NIH Spending Sectors

10.3.18.            Analysis by Grant Activity

10.3.19.            Most Prominent Program Officers

10.3.20.            Regional Distribution of Recipient Organization

10.4.                 Grant Attractiveness Analysis

FUNDING AND INVESTMENT ANALYSIS

11.1.                 Chapter Overview

11.2.                 Types of Funding

11.3.                 Synthetic Lethality: List of Funding and Investments

11.3.1.              Analysis by Number of Instances

11.3.2.              Analysis by Amount Invested

11.3.3.              Analysis by Type of Funding

11.3.4.              Analysis by Type of Company

11.3.5.              Analysis by Purpose of Funding

11.3.6.              Analysis by Type of Molecule

11.3.7.              Analysis by Synlet Target

11.3.8.              Analysis by Therapeutic Area

11.3.9.              Analysis by Target Indication

11.3.10.            Analysis by Geography

11.3.11.            Most Active Players

11.3.12.            Most Active Investors

11.4.                 Concluding Remarks

TARGET BENCHMARK ANALYSIS

12.1.                 Chapter Overview

12.2.                 Scope and Methodology

12.3.                 Target Benchmark Analysis

12.3.1.              Clinically Validated Synlet Targets

12.3.2.              Preclinically Validated Synlet Targets

12.3.3.              Early Stage Research Validated Synlet Targets

12.4.                 Initiatives of Big Pharmaceutical Players

12.5.                 Concluding Remarks

ROLE OF COMPANION DIAGNOSTICS IN SYNTHETIC LETHALITY

13.1.                 Chapter Overview

13.2.                 Concept of Companion Diagnostics

13.3.                 Development of Companion Diagnostics

13.3.1.              Co-development / Parallel Development Approach

13.3.2.              Development of Companion Diagnostics Post Drug Approval

13.3.3.             Development of already Approved Companion Diagnostics for New Drugs / Disease                     Indications

13.4.                 Advantages of Companion Diagnostics

13.5.                 Applications of Companion Diagnostics in Synthetic Lethality

13.6.                 Companion Diagnostics: List of Available / Under Development Tests

13.6.1.              Analysis by Synlet Target

13.6.2.              Analysis by Type of Biomarker

13.6.3.              Analysis by Type of Biomarker and Technology

13.6.4.              Analysis by Target Indication

13.6.5.              Analysis by Developer and Synlet Target

13.6.6.              Most Prominent Developers

13.7.                 Case-in-Point: Companion Diagnostics for Commercially Available Poly-ADP Ribose                    Polymerase (PARP) Inhibitors

13.7.1.              Companion Diagnostics Test for Niraparib

13.7.1.1.           Product Overview

13.7.1.2.           Working Process

13.7.1.3.           Collaborations

13.7.2.              Companion Diagnostics Test for Olaparib

13.7.2.1.           Product Overview

13.7.2.2.           Working Process

13.7.2.3.           Collaborations

13.7.3.              Companion Diagnostics Test for Rucaparib

13.7.3.1.           Product Overview

13.7.3.2.           Collaborations

13.7.4.              Companion Diagnostics Test for Talazoparib

13.7.4.1.           Product Overview

13.7.4.2.           Collaborations

13.8.                 Future Perspective

MARKET FORECAST

14.1.                 Chapter Overview

14.2.                 Scope and Limitations

14.3.                 Forecast Methodology and Key Assumptions

14.4.                 Overall Synthetic Lethality-based Drugs Market, 2019-2030

14.4.1.             Synthetic Lethality-based Drugs Market: Distribution by Type of Molecule, 2019 and 2030

14.4.1.1.           Synthetic Lethality-based Drugs Market for Small Molecule, 2019-2030

14.4.1.2.           Synthetic Lethality-based Drugs Market for Biologic, 2019-2030

14.4.2.             Synthetic Lethality-based Drugs Market: Distribution by Synlet Target, 2019 and 2030

14.4.2.1.           Synthetic Lethality-based Drugs Market for APE1 / REF-1, 2019-2030

14.4.2.2.           Synthetic Lethality-based Drugs Market for CHK1, 2019-2030

14.4.2.3.           Synthetic Lethality-based Drugs Market for GLS1, 2019-2030

14.4.2.4.           Synthetic Lethality-based Drugs Market for PARP, 2019-2030

14.4.2.5.           Synthetic Lethality-based Drugs Market for Polθ, 2019-2030

14.4.2.6.           Synthetic Lethality-based Drugs Market for WEE1, 2019-2030

14.4.3.             Synthetic Lethality-based Drugs Market: Distribution by Target Indication, 2019 and 2030

14.4.3.1.           Synthetic Lethality-based Drugs Market for Breast Cancer, 2019-2030

14.4.3.2.           Synthetic Lethality-based Drugs Market for Cervical / Anogenital Cancer, 2019-2030

14.4.3.3.           Synthetic Lethality-based Drugs Market for Diabetic Macular Edema, 2019-2030

14.4.3.4.           Synthetic Lethality-based Drugs Market for Gastric Cancer, 2019-2030

14.4.3.5.           Synthetic Lethality-based Drugs Market for Lung Cancer, 2019-2030

14.4.3.5.           Synthetic Lethality-based Drugs Market for Ovarian Cancer, 2019-2030

14.4.3.7.           Synthetic Lethality-based Drugs Market for Renal Cell Cancer, 2019-2030

14.4.4.             Synthetic Lethality-based Drugs Market: Distribution by Route of Administration, 2019                  and 2030

14.4.4.1.           Synthetic Lethality-based Drugs Market for Oral Therapies, 2019-2030

14.4.4.2.           Synthetic Lethality-based Drugs Market for Intravenous Therapies, 2019-2030

14.4.5.             Synthetic Lethality-based Drugs Market: Distribution by Geography, 2019 and 2030

14.4.5.1.           Synthetic Lethality-based Drugs Market in the US, 2019-2030

14.4.5.2.           Synthetic Lethality-based Drugs Market in France, 2019-2030

14.4.5.3.           Synthetic Lethality-based Drugs Market in Germany, 2019-2030

14.4.5.4.           Synthetic Lethality-based Drugs Market in Italy, 2019-2030

14.4.5.5.           Synthetic Lethality-based Drugs Market in Spain, 2019-2030

14.4.5.6.           Synthetic Lethality-based Drugs Market in the UK, 2019-2030

14.4.5.8.           Synthetic Lethality-based Drugs Market in Australia, 2019-2030

14.4.5.7.           Synthetic Lethality-based Drugs Market in China, 2019-2030

14.4.5.8.           Synthetic Lethality-based Drugs Market in Japan, 2019-2030

14.4.6.              Product-wise Sales Forecast

14.4.6.1            Niraparib (GlaxoSmithKline)

14.4.6.1.1.         Target Patient Population

14.4.6.1.2.         Sales Forecast (USD Million)

14.4.6.1.3.         Net Present Value (USD Million)

14.4.6.1.4.         Value Creation Analysis

14.4.6.2.           Olaparib (AstraZeneca)

14.4.6.2.1.         Target Patient Population

14.4.6.2.2.         Sales Forecast (USD Million)

14.4.6.2.3.         Net Present Value (USD Million)

14.4.6.2.4.         Value Creation Analysis

14.4.6.3.           Rucaparib (Clovis Oncology)

14.4.6.3.1.         Target Patient Population

14.4.6.3.2.         Sales Forecast (USD Million)

14.4.6.3.3.         Net Present Value (USD Million)

14.4.6.3.4.         Value Creation Analysis

14.4.6.4.           Talazoparib (Pfizer)

14.4.6.4.1.         Target Patient Population

14.4.6.4.2.         Sales Forecast (USD Million)

14.4.6.4.3.         Net Present Value (USD Million)

14.4.6.4.4.         Value Creation Analysis

14.4.6.5.           Pamiparib (BeiGene)

14.4.6.5.1.         Target Patient Population

14.4.6.5.2.         Sales Forecast (USD Million)

14.4.6.5.3.         Net Present Value (USD Million)

14.4.6.5.4.         Value Creation Analysis

14.4.6.6.           Veliparib (AbbVie)

14.4.6.6.1.         Target Patient Population

14.4.6.6.2.         Sales Forecast (USD Million)

14.4.6.6.3.         Net Present Value (USD Million)

14.4.6.6.4.         Value Creation Analysis

14.4.6.7.           Adavosertib (AstraZeneca)

14.4.6.7.1.         Target Patient Population

14.4.6.7.2.         Sales Forecast (USD Million)

14.4.6.7.3.         Net Present Value (USD Million)

14.4.6.7.4.         Value Creation Analysis

14.4.6.8.           APX3330 (Apexian Pharmaceuticals)

14.4.6.8.1.         Target Patient Population

14.4.6.8.2.         Sales Forecast (USD Million)

14.4.6.8.3.         Net Present Value (USD Million)

14.4.6.8.4.         Value Creation Analysis

14.4.6.9.           CX-5461 (Senhwa Biosciences)

14.4.6.9.1.         Target Patient Population

14.4.6.9.2.         Sales Forecast (USD Million)

14.4.6.9.3.         Net Present Value (USD Million)

14.4.6.9.4.         Value Creation Analysis

14.4.6.10.          SRA737-01 (Sierra Oncology)

14.4.6.10.1.       Target Patient Population

14.4.6.10.2.       Sales Forecast (USD Million)

14.4.6.10.3.       Net Present Value (USD Million)

14.4.6.10.4.       Value Creation Analysis

14.4.6.11.          SRA737-02 (Sierra Oncology)

14.4.6.11.1.       Target Patient Population

14.4.6.11.2.       Sales Forecast (USD Million)

14.4.6.11.3.       Net Present Value (USD Million)

14.4.6.11.4.       Value Creation Analysis

14.4.6.12.          Telaglenastat (Calithera Biosciences)

14.4.6.12.1.       Target Patient Population

14.4.6.12.2.       Sales Forecast (USD Million)

14.4.6.12.3.       Net Present Value (USD Million)

14.4.6.12.4.       Value Creation Analysis

14.4.7.              Concluding Remarks

CONCLUDING REMARKS

EXECUTIVE INSIGHTS

16.1.                 Chapter Overview

16.2.                 Artios Pharma

16.2.1.              Company / Organization Snapshot

16.2.2.              Interview Transcript: Simon Boulton, Vice President, Science Strategy

16.3.                 IMPACT Therapeutics

16.3.1.              Company / Organization Snapshot

16.3.2.              Interview Transcript: Yi Xu, Associate Director

16.4.                 Harvard Medical School

16.4.1.              Company / Organization Snapshot

16.4.2.              Interview Transcript: Norbert Perrimon, Professor, Department of Genetics

16.5.                 Panjab University

16.5.1.              Company / Organization Snapshot

16.5.2.              Interview Transcript: Vivek Dharwal, Professor, Department of Biochemistry

16.6.                 UbiQ

16.6.1.              Company / Organization Snapshot

16.6.2.              Interview Transcript: Alfred Nijkerk, Chief Executive Officer

APPENDIX 1: TABULATED DATA

APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

The Synthetic Lethality-based Drugs And Targets Market Is Projected To Grow At An Annualized Rate Of ~18%, Till 2030

The synthetic lethality-based drugs and targets market is projected to grow at an annualized rate of ~18%, till 2030

Share:

Comments

FREE BLOG/SBM SITES

BLOG SITES

SBM SITES

CLASSIFIED SITES

Categories

Other related blogs

KetoAdvanced

By : KetoAdvanced

The advantage of CPR knowledge during Corona pandemic

By : Ashlyn Lemieux

VaryForte

By : VaryForte

Buy Abortion Pills Online Usa and Rid from Unwanted Pregnancy

By : Safematernology